GNE-477 is a potent and selective inhibitor of PI3K and mTOR signaling pathways, which play key roles in cell growth, proliferation, and survival. It is primarily used in cancer research to study tumor progression and evaluate therapeutic strategies, especially in cancers driven by dysregulation of the PI3K/AKT/mTOR pathway. Due to its ability to simultaneously target both PI3K and mTOR, GNE-477 provides a dual inhibitory effect that can overcome limitations seen with single-pathway inhibitors. It has been utilized in preclinical studies to assess antitumor efficacy, apoptosis induction, and inhibition of cell proliferation in various cancer cell lines. Its application is mainly confined to laboratory research and drug development rather than clinical use.